Nuvectis Pharma, Inc. (NVCT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 19.65M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 6.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -28.87M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.65M | (m) | $6.49M | $-28.87M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $18.58M | (m) | $6.51M | $-28.27M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $18.15M | (m) | $6.03M | $-27.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $17.56M | (m) | $5.70M | $-26.41M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $14.61M | (m) | $5.40M | $-22.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $13.94M | (m) | $4.93M | $-21.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $12.92M | (m) | $4.86M | $-19.85M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $12.69M | (m) | $4.94M | $-20.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $14.35M | (m) | $4.91M | $-22.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $15.67M | (m) | $4.60M | $-23.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $15.38M | (m) | $4.71M | $-22.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $15.51M | (m) | $3.97M | $-22.81M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $15.55M | (m) | $3.39M | $-22.59M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $13.79M | (m) | $2.95M | $-20.39M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $13.23M | (m) | $1.71M | $-19.23M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $9.54M | (m) | $1.89M | $-12.89M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |